Corporadelic
A series on the intersection of psychedelics and capitalism,
and the early investors making it happen.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Corporadelic
A series on the intersection of psychedelics and capitalism,
and the early investors making it happen.
Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?
As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.
Talking Psychedelic Capitalism in a WeWork Ballroom
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.
Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course
The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.
Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress
“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”
Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?
Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?
As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.
Talking Psychedelic Capitalism in a WeWork Ballroom
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.
Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course
The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.
Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress
“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”
Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?
Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?
As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.
Talking Psychedelic Capitalism in a WeWork Ballroom
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.
Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS
After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.
“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course
The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.
Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress
“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”
Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency
Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?